Respiratory function

[키워드] accompany affected Anti-inflammatory anti-inflammatory drug anti-inflammatory effect Antiviral appear approach baseline benefit Biomarkers biomarkers of inflammation C-reactive protein C-reactive protein (CRP Chain Reaction clinical pharmacology clinical response collected compassionate use compassionate-use contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection criteria CRP Cytokines during treatment Dyspnea Effect effective Evidence hyperinflammation Hypothesis immune cells inclusion criteria Infection Inflammation Inflammatory response inhibit interferons interstitial pneumonia invasive ventilation JAK inhibitor jak inhibitors Jak-STAT janus Janus kinase less Lungs management mechanical ventilation mmHg need for oxygen oxygen oxygen saturation oxygen support PaO pathway Patient patients hospitalized patients with SARS-CoV-2 polymerase chain polymerase chain reaction positive present pro-inflammatory pro-inflammatory cytokines prognostic progression provided reduce reduced reduction reinforcement respiratory Respiratory function ruxolitinib SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome Side effect significantly more STAT Support Symptom systemic inflammation target the disease therapeutic therapeutic agent therapeutic agents Topic Treatment type I interferon type I interferons Ventilation were recorded
[DOI] 10.1111/cts.12971 PMC 바로가기 [Article Type] Article